Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Systemic sclerosis disease modification clinical trials design: quo vadis?

Literature DB >> 22422541

Systemic sclerosis disease modification clinical trials design: quo vadis?

Fabian A Mendoza¹, Lynette L Keyes-Elstein, Sergio A Jimenez.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Antirheumatic Agents

Year: 2012 PMID： 22422541 PMCID： PMC3386473 DOI： 10.1002/acr.21667

Source DB: PubMed Journal: Arthritis Care Res (Hoboken) ISSN： 2151-464X Impact factor: 4.794

× No keyword cloud information.

38 in total

1. The randomized placebo-phase design for clinical trials.

Authors: B Feldman; E Wang; A Willan; J P Szalai
Journal: J Clin Epidemiol Date: 2001-06 Impact factor: 6.437

2. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.

Authors: J R Seibold; J H Korn; R Simms; P J Clements; L W Moreland; M D Mayes; D E Furst; N Rothfield; V Steen; M Weisman; D Collier; F M Wigley; P A Merkel; M E Csuka; V Hsu; S Rocco; M Erikson; J Hannigan; W S Harkonen; M E Sanders
Journal: Ann Intern Med Date: 2000-06-06 Impact factor: 25.391

3. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.

Authors: J E Pope; N Bellamy; J R Seibold; M Baron; M Ellman; S Carette; C D Smith; I M Chalmers; P Hong; D O'Hanlon; E Kaminska; J Markland; J Sibley; L Catoggio; D E Furst
Journal: Arthritis Rheum Date: 2001-06

4. A modified scleroderma skin scoring method.

Authors: M B Kahaleh; G L Sultany; E A Smith; J E Huffstutter; C B Loadholt; E C LeRoy
Journal: Clin Exp Rheumatol Date: 1986 Oct-Dec Impact factor: 4.473

5. A three-stage clinical trial design for rare disorders.

Authors: V E Honkanen; A F Siegel; J P Szalai; V Berger; B M Feldman; J N Siegel
Journal: Stat Med Date: 2001-10-30 Impact factor: 2.373

6. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial: lessons learned.

Authors: Philip J Clements; James R Seibold; Daniel E Furst; Maureen Mayes; Barbara White; Fredrick Wigley; Michael D Weisman; Water Barr; Larry Moreland; Thomas A Medsger; Virginia Steen; Richard W Martin; David Collier; Arthur Weinstein; Edward Lally; John Varga; Steven R Weiner; Brian Andrews; Micha Abeles; Weng Kee Wong
Journal: Semin Arthritis Rheum Date: 2004-02 Impact factor: 5.532

7. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma.

Authors: G P Rodnan; E Lipinski; J Luksick
Journal: Arthritis Rheum Date: 1979-02

8. Systemic and cell type-specific gene expression patterns in scleroderma skin.

Authors: Michael L Whitfield; Deborah R Finlay; John Isaac Murray; Olga G Troyanskaya; Jen-Tsan Chi; Alexander Pergamenschikov; Timothy H McCalmont; Patrick O Brown; David Botstein; M Kari Connolly
Journal: Proc Natl Acad Sci U S A Date: 2003-10-06 Impact factor: 11.205

9. Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis.

Authors: B White; E A Bauer; L A Goldsmith; M C Hochberg; L M Katz; J H Korn; P A Lachenbruch; E C LeRoy; M P Mitrane; H E Paulus
Journal: Arthritis Rheum Date: 1995-03

10. Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design.

Authors: Chunqin Deng; Kim Hanna; Vera Bril; Marinos C Dalakas; Peter Donofrio; Pieter A van Doorn; Hans-Peter Hartung; Ingemar S J Merkies
Journal: J Neurol Date: 2011-08-07 Impact factor: 4.849

3 in total